Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
125 results about "Blepharitis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An inflammation of the eyelids.
Eyelid Care Appliance
ActiveUS20150182415A1Evaluate and user performanceEvaluate performanceEye surgeryBrush bodiesBlepharitisSelf-Administered
Disclosed herein is an improved eyelid care appliance and method of using such appliance for preventing and treating blepharitis and mammalian meibomian gland dysfunction caused by gland obstruction. The method and apparatus of the invention enable restoration and maintenance of eyelid hygiene and the natural flow of secretions from the meibomian glands. A preferred embodiment of the apparatus comprises an oscillating spongehead affixed to the distal end of the eyelid care appliance that is equipped with a video camera, near field communications link, and a display, thereby enabling a user to “fly” the spongehead onto an eyelid margin for self-administered cleaning of the user's eyelid margins. The spongehead can be impregnated with topical pharmacologic or cleansing agents to better facilitate cleaning and therapeutic efficacy.
Owner:TEENY CLEAN
Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
InactiveUS20110059925A1Improving lid margin functionRelieve ocular discomfortBiocideSenses disorderDiseaseOphthalmology
The present invention provides a mucoadhesive broad spectrum antibiotic with anti-inflammatory characteristics with strong tissue penetration for improving lid margin function and the treatment of diseases associated therewith. The present invention further provides compositions and methods for treating and / or preventing the signs and / or symptoms of blepharitis and dry eye disease.
Owner:DONNENFELD ERIC
Amelioration of macular degeneration and other ophthalmic diseases
Methods for the treatment or prevention of a number of ocular diseases or disorders are disclosed. In particular, methods are disclosed for the amelioration of macular degeneration, diabetic retinopathy and other retinopathies, as well as uveitis, presbyopia, dry eye, glaucoma, blepharitis and rosacea of the eye. The methods comprise administration of a compositions comprising an ophthalmologically acceptable carrier or diluent and a hydoxylamine compound in a therapeutically sufficient amount to prevent, retard the development or reduce the symptoms of one or more of the ophthalmic conditions.
Owner:COLBY PHARMA CO
Ophthalmic, otic or nasal pharmaceutical composition and the use thereof
InactiveUS20100222308A1Effective treatmentPreventing increase of bacterial infection riskAntibacterial agentsBiocideInfective rhinitisNose
The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.
Owner:SHENZHEN REGOO LAB
Method for treating ophthalmic diseases using rho kinase inhibitor compounds
This invention is directed to methods of preventing or treating ocular diseases with inflammation, excessive cell proliferation, remodeling, neurite retraction, corneal neurodegeneration, excessive vaso-permeability and edema. Particularly, this invention relates to methods treating ocular diseases such as allergic conjunctivitis, corneal hyposensitivity, neurotrophic keratopathy, dry eye disease, proliferative vitreal retinopathy, macular edema, macular degeneration, and blepharitis, using novel Rho kinase inhibitor compounds. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.
Owner:INSPIRE PHARMA
Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof
ActiveUS20130303502A1Increase concentrationMaintaining osmolalityOrganic active ingredientsOrganic chemistry methodsDiseaseRespiratory disease
The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and / or preventing the signs and / or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
Owner:NICOX OPHTHALMICS
Method for treating ocular demodex
InactiveUS20090214676A1Equally distributedFacilitate eradicationBiocideSenses disorderDiseaseDemodex
The present invention relates to a method for treating a disorder chosen from ocular Demodex, Demodex-induced blepharitis, rosacea, acne, and meibomian gland dysfunction in a patient in need thereof, comprising administering to the patient a composition comprising a therapeutically effective amount of a substance chosen from at least one of an isoprenoidal essential oil such as Tea Tree Oil; Terpinen-4-ol; (+)-Carvone; alpha-Terpineol; Cardinene; d-Carvone; l-Carvone; gamma-Terpinene; alpha-Terpinene; 1,8-Cineole; alpha-Terpineol; para-Cimene; alpha-Pinene; Limonene; (R)-(+)-Limonene; alpha-Thugene; Eucalyptol; (+)-Ledene; Cuminic Aldehyde; and Myrcene; the administration comprising contacting or scrubbing an affected area of skin or hair, or eyelid margin and lashes of the patient with the composition; also disclosed are a method for treating mange and mite infestations on a mammalian animal; and kits for in-office and at home treatments of the disorders.
Owner:TISSUETECH INC
Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
This invention is directed to prodrugs of rho kinase (ROCK) inhibitors. These prodrugs are in general the ester or the amide derivatives of the parent compounds. These prodrugs are often weak inhibitors of ROCK, but their parent compounds have good activities. Upon instillation into the eyes, the ester or the amide group of these prodrugs is rapidly hydrolyzed into alcohol, amine, or acid, and the prodrugs are converted into the active base compounds. The prodrugs of ROCK inhibitors provide several advantages such as delivery of higher concentrations of the active species into the target site and reduction of ocular discomfort. The invention is also directed to a method of treating ophthalmic diseases such as glaucoma, allergic conjunctivitis, macular edema, macular degeneration, and blepharitis, by administering an effective amount of a ROCK prodrug compound of Formula I to the eyes of the patient in need of.
Owner:MERCK SHARP & DOHME CORP
Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
ActiveUS20050239895A1No irritationInhibit deteriorationBiocideOrganic active ingredientsScleritisPhenylacetic acid
An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
Owner:SENJU PHARMA CO LTD
Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Owner:SENJU PHARMA CO LTD
Medicament composition for eyes or nose, and uses thereof
The present invention provides a combination of medicines for eyes or ears and nose, which comprises levofloxacin and loteprednol carbon ester; wherein, the weight ratio of the loteprednol carbon ester to the levofloxacin is between 1 to 0.2 and 1 to 5. The combination of medicine for eyes or ears and nose of the present invention is used for curing conjunctivitis, keratitis, blepharitis, dacryocystitis, hordeolum, corneal ulcer and eye infection with inflammation of eyes or even inflammation of tissue around eyes. The combination is also used for preventing bacterial infection risk after ophthalmology operation or eye injury and inflammation of the infected region, or the combination is used for curing or alleviating bacterial infection and tissue inflammation of the infected region after ophthalmology operation or eye injury, or cure tympanitis, otitis externa and infectious rhinitis.
Owner:SHENZHEN REGOO LAB
Intranasal stimulation for treatment of meibomian gland disease and blepharitis
ActiveUS20170312521A1Improve secreted meibum qualityImprovement in secreted meibum qualityHead electrodesExternal electrodesBlepharitisDisease
Described here are devices, systems, and methods for treating meibomian gland disease and / or blepharitis by providing intranasal stimulation. Generally, the devices may deliver electrical stimulation to the nasal mucosa. Intranasal stimulation may unblock obstructed meibomian glands and increase the lipid content of tears, both acutely during stimulation and subsequent to intranasal stimulation. The methods may include an initial round of stimulation to unblock obstructed meibomian glands, and subsequent shorter rounds of stimulation to cause meibum secretion and maintain the open glands.
Owner:OCULEVE
Compositions and methods for using same for treating posterior blepharitis
ActiveUS20130065867A1Efficient changeEliminating reducing related symptomBiocideOrganic active ingredientsPosterior blepharitisOmega 3 index
This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids.
Owner:PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS LLC
Methods for treating ocular inflammatory diseases
A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
Owner:SUN PHARMA INDS
Self-Warming Hands Free Eye Compress
Warm compresses are the most widely prescribed effective medical therapy for several common eye conditions namely dry eye syndrome, blepharitis and chalazia. These problems are caused by blockage of natural oil flow through pores located behind the eyelashes (meibomian glands). Warm compresses open these pores and restores normal flow of natural oils to the eye surface; these oils moisturize the eye by preventing evaporation of tears from the eye surface. The novel aspects of this invention that make it unique include the ability to generate long lasting, self-perpetuating moist heat, with hands free convenience. By allowing patients to continue to work, play, read or watch television while receiving the therapeutic benefits of a moist warm compress this invention is highly likely to increase compliance and improve quality of life for millions of patients with these common and highly troublesome eye conditions.
Owner:CHEN VICKI MIN
Amelioration of macular degeneration and other ophthalmic diseases
Methods for the treatment or prevention of a number of ocular diseases or disorders are disclosed. In particular, methods are disclosed for the amelioration of macular degeneration, diabetic retinophaty and other retinopathies, as well as uveitis, presbyopia, dry eye, glaucoma, blepharitis and rosacea of the eye. The methods comprise administration of a compositions comprising an ophthalmologically acceptable carrier or diluent and a hydoxylamine compound in a therapeutically sufficient amount to prevent, retard the development or reduce the symptoms of one or more of the ophthalmic conditions.
Owner:COLBY PHARMA CO
Ophthalmic compositions
ActiveUS20180008538A1High expressionSenses disorderAmide active ingredientsUveitisMedium-chain triglyceride
The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and / or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis, episcleritis and uveitis.
Owner:LAB SALVAT
Method of treating blepharitis
ActiveUS20100022465A1Relieve symptomsReducing clinical signBiocideSenses disorderContact lens intoleranceAzithromycin
The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis.
Owner:INSPIRE PHARMA
Metronidazole ophthalmic gel and preparation method and application thereof
InactiveCN102552114APromote absorptionExtended stayAntibacterial agentsOrganic active ingredientsAnaerobic infectionAnaerobic bacteria
The invention discloses metronidazole ophthalmic gel and a preparation method and an application thereof, which belong to the technical field of medicine. Metronidazole serving as a related medicinal active ingredient is prepared into ophthalmic gel for the first time. The metronidazole ophthalmic gel is applied to prevention and treatment of blepharitis ciliaris, hordeolum and conjunctivitis caused by worm acarus infection, and a dry eye syndrome caused by meibomian gland dysfunction, and is applied to prevention and treatment of infection of acanthamoeba protozoan and anaerobic bacteria in the wearing process of corneal contact lenses. The metronidazole ophthalmic gel consists of metronidazole and a pharmaceutically-acceptable vector, and the using amount of metronidazole in every 100g of the metronidazole ophthalmic gel is 0.1-3.0g by weight.
Owner:段亚东
Method of treating blepharitis
ActiveUS8349806B2Reducing symptom and clinical signReduce exposureBiocideSenses disorderPosterior blepharitisAzithromycin
The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis.
Owner:INSPIRE PHARMA
Method for treating blepharitis
The present invention is related to a method for treating blepharitis, the method comprising administering to an ocular area of a subject in need thereof a composition comprising about 0.001% to about 0.01% (w / v) dexamethasone and an antibiotic, wherein the composition is substantially free of lipids, and wherein the composition is ophthalmically acceptable.
Owner:RIOLAN TECH
Method for treating blepharitis
InactiveUS20130274214A1Quality improvementReduce inflammationBiocideCarbohydrate active ingredientsAzithromycinRetinoid
This invention relates to methods of treating blepharitis. The methods comprise identifying a patient suffering from blepharitis, and topically administering to the eyes of the patient an effective amount of azithromycin and an effective amount of a retinoid. The method is useful in relieving blepharitis signs and symptoms. This invention also relates to a pharmaceutical composition comprising azithromycin and a retinoid such as retinyl palmitate.
Owner:MERCK SHARP & DOHME CORP
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.
Owner:TARSUS PHARMA INC
Device for treating an ocular disorder
An instrument for removing debris from an eye during the treatment of an ocular disorder has a swab and a rigid member. The swab includes a tip portion sized to provide access to the debris on an eyelid of the eye. The rigid member has a distal end portion affixed to the swab and a proximal end portion with a cross-sectional member profile. The cross-sectional member profile is non-circular and has a first groove. The first groove extends longitudinally along the proximal end portion for cooperating with a chuck such that rotation of the proximal end portion within the chuck is inhibited.
Owner:BLEPHEX
Non-steroid anti-inflammatory medicine for external use for ophthalmology
ActiveCN102058581AGood intraocular penetrationStrong penetrating powerOrganic active ingredientsAntipyreticDiseaseSide effect
The invention relates to a eye gel. The content of tiaprofenic acid or the salts thereof in every 100 weight parts of the medicine is 0.1-1.0 weight parts. The non-steroid anti-inflammatory medicine for external use for ophthalmology has good permeability in eyes and low toxic and adverse effects, and can be used for treating and preventing diseases of outer eye and anterior segment of eye, caused by non-infectious inflammations, such as blepharitis, conjunctivitis, keratitis, sclerotitis, episcleritis, iridocyclitis and postoperative inflammation.
Owner:GUANGDONG WHOLEWIN TECH
Antimicrobial compositions and articles
InactiveUS20160330969A1Extension of timeBiocidePharmaceutical delivery mechanismBlepharitisHypochlorous acid
The invention provides antimicrobial cleansing compositions comprising hypochlorous acid, in the pH range 2.5 to 6.0, and disposable wiping articles impregnated with these compositions, along with chlorine-impermeable and chlorine-resistant packaging for the compositions and articles. The invention also provides methods of treating blepharitis and acne, and of disinfecting the skin, with these compositions and articles.
Owner:OCONNELL JR JOHN F
Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
ActiveUS20150337006A1Modifies release timeExtend posting timeOrganic active ingredientsSynthetic resin layered productsDiseaseRespiratory disease
The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and / or preventing the signs and / or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
Owner:NICOX OPHTHALMICS
Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
The present invention relates to compositions comprising at least one flavonoid for the treatment or amelioration of a disease or disorder of the eye and / or the adnexa of the eye in an animal subject, including a human being. More particularly, this invention relates to a composition for the treatment of conjunctivitis, keratoconjunctivitis sicca, and blepharitis. The invention furthermore relates to a pharmaceutical composition comprising at least one flavonoid, such as for example a topical formulation. The source of the flavonoids may be, but are not restricted to, flavonoids extracted from citrus plants. The compositions may furthermore optionally be used in combination with an eyecleaner or eyewash, which may comprise at least one flavonoid.
Owner:OCUMEDIC
Transdermal drug delivery system and method of using the same
InactiveUS8900626B2Effective treatmentImprove permeabilityOrganic active ingredientsBiocideDiseaseActive agent
A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction.
Owner:SENJU USA
Lomefloxacin hydrochloride eye drops and preparation method and application thereof
ActiveCN102670493AIncrease viscosityExtended stayAntibacterial agentsOrganic active ingredientsBacterial ConjunctivitisTherapeutic effect
The invention discloses lomefloxacin hydrochloride eye drops and a preparation method and application thereof. The lomefloxacin accounts for 0.3% of the active components. The preparation also comprises a tackifier, a buffer salt system, a wetting agent, an isoosmotic adjusting agent, a pH adjusting agent and a bacteriostatic agent, and is suitable for treating the external eye infections such asacute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomiantis, dacryocystitis, keratitis, keratohelcosis and the like caused by sensitive pathogenic bacteria. The product is characterized in that: by adding the sodium hyaluronate with a tackifying effect and a moisturizing effect, the viscosity of the lomefloxacin hydrochloride eye drops is improved, the fluidics property thereof is changed, the residence time of the eye drops in the eyes is prolonged, the sufficient absorption of the medicine is ensured, the bioavailability is increased, the administration times are reduced, the compliance of a patient is improved, and an effective treatment effect is realized.
Owner:KANGYA OF NINGXIA PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com